Brief: Xintela Completes Clinical Study With Xstem In Knee Osteoarthritis
15/08/2025 07:14
Aug 15 (Reuters) - Xintela AB XINT.ST: COMPLETES CLINICAL STUDY WITH XSTEM IN KNEE OSTEOARTHRITIS XINTELA PREVIOUSLY COMMUNICATED POSITIVE INTERIM RESULTS UP TO 18 MONTHS AFTER TREATMENT AND NOW COMPLETED COLLECTION OF 24-MONTHS DATA FOR HIGHEST DOSE LEVEL Source text: ID:nMFN3M9pDH Further company coverage: XINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects